The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa

Schneider, Karen, Nwizu, Chidi, Kaplan, Richard, Anderson, Jonathan, Wilson, David P., Emery, Sean, Cooper, David A. and Boyd, Mark A. (2013) The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa. PLoS One, 8 2: . doi:10.1371/journal.pone.0054435


Author Schneider, Karen
Nwizu, Chidi
Kaplan, Richard
Anderson, Jonathan
Wilson, David P.
Emery, Sean
Cooper, David A.
Boyd, Mark A.
Title The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa
Journal name PLoS One   Check publisher's open access policy
ISSN 1932-6203
Publication date 2013-02-15
Sub-type Article (original research)
DOI 10.1371/journal.pone.0054435
Open Access Status DOI
Volume 8
Issue 2
Total pages 7
Place of publication San Francisco, CA, United States
Publisher Public Library of Science
Language eng
Formatted abstract
Background: There is an urgent need to improve the evidence base for provision of second-line antiretroviral therapy (ART) following first-line virological failure. This is particularly the case in Sub-Saharan Africa where 70% of all people living with HIV/AIDS (PHA) reside. The aim of this study was to simulate the potential risks and benefits of treatment simplification in second-line therapy compared to the current standard of care (SOC) in a lower-middle income and an upper-middle income country in Sub-Saharan Africa.

Methods: We developed a microsimulation model to compare outcomes associated with reducing treatment discontinuations between current SOC for second-line therapy in South Africa and Nigeria and an alternative regimen: ritonavir-boosted lopinavir (LPV/r) combined with raltegravir (RAL). We used published studies and collaborating sites to estimate efficacy, adverse effect and cost. Model outcomes were reported as incremental cost effectiveness ratios (ICERs) in 2011 USD per quality adjusted life year ($/QALY) gained.

Results: Reducing treatment discontinuations with LPV/r+RAL resulted in an additional 0.4 discounted QALYs and increased the undiscounted life expectancy by 0.8 years per person compared to the current SOC. The average incremental cost was $6,525 per treated patient in Nigeria and $4,409 per treated patient in South Africa. The cost-effectiveness ratios were $16,302/QALY gained and $11,085/QALY gained for Nigeria and South Africa, respectively. Our results were sensitive to the probability of ART discontinuation and the unit cost for RAL.

Conclusions: The combination of raltegravir and ritonavir-boosted lopinavir was projected to be cost-effective in South Africa. However, at its current price, it is unlikely to be cost-effective in Nigeria.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 18 Mar 2017, 01:00:47 EST by Web Cron on behalf of Learning and Research Services (UQ Library)